单位：[1]China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Ctr Resp Med, Beijing, Peoples R China[2]Natl Ctr Resp Med, Beijing, Peoples R China[3]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China[4]Chinese Acad Med Sci, Inst Resp Med, Peking Union Med Coll, Beijing, Peoples R China[5]Chinese Acad Med Sci, Sch Basic Med, Dept Physiol,Peking Union Med Coll, State Key Lab Med Mol Biol,Inst Basic Med Sci, Beijing, Peoples R China[6]China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with a poor prognosis. Although dihydromyricetin (DHM), extracted from vine tea and other Ampelopsis species, has been proven to have anti-inflammatory and antioxidant functions, the effects of DHM on IPF remain unclear.Methods: The effects of DHM on the differentiation, migration, proliferation, and respiratory functions of primary mouse lung fibroblasts (PMLFs) and primary human lung fibroblasts (PHLFs) were detected by western blotting, the Transwell assay, EdU staining, and the Mito Stress test. Then, the impacts of DHM on bleomycin (BLM)-induced pulmonary fibrosis were evaluated by pathological staining, western blotting, and coimmunofluorescence staining. The signaling pathway influenced by DHM was also investigated.Results: DHM could regulate the differentiation of fibroblasts to myofibroblasts and suppress the abnormal migration, proliferation, and respiratory functions of myofibroblasts induced by TGF-beta 1 or myofibroblasts from IPF patients. DHM could also alleviate pulmonary fibrosis induced by BLM. All these effects were achieved by regulating the STAT3/p-STAT3/GLUT1 signaling pathway.Conclusion: DHM could regulate the abnormal functions of myofibroblasts induced by TGF-beta 1 and myofibroblasts from IPF patients and alleviate pulmonary fibrosis induced by BLM; thus, DHM might be a candidate medicinal treatment for IPF.
基金：
National Natural Science Foundation of China [81870056, 81800067]
第一作者单位：[1]China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Ctr Resp Med, Beijing, Peoples R China[2]Natl Ctr Resp Med, Beijing, Peoples R China[3]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China[4]Chinese Acad Med Sci, Inst Resp Med, Peking Union Med Coll, Beijing, Peoples R China
通讯作者：
通讯机构：[1]China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Ctr Resp Med, Beijing, Peoples R China[2]Natl Ctr Resp Med, Beijing, Peoples R China[3]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China[4]Chinese Acad Med Sci, Inst Resp Med, Peking Union Med Coll, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Li Zhen,Geng Jing,Xie Bingbing,et al.Dihydromyricetin Alleviates Pulmonary Fibrosis by Regulating Abnormal Fibroblasts Through the STAT3/p-STAT3/GLUT1 Signaling Pathway[J].FRONTIERS in PHARMACOLOGY.2022,13:doi:10.3389/fphar.2022.834604.
APA：
Li, Zhen,Geng, Jing,Xie, Bingbing,He, Jiarui,Wang, Jing...&Wang, Chen.(2022).Dihydromyricetin Alleviates Pulmonary Fibrosis by Regulating Abnormal Fibroblasts Through the STAT3/p-STAT3/GLUT1 Signaling Pathway.FRONTIERS in PHARMACOLOGY,13,
MLA：
Li, Zhen,et al."Dihydromyricetin Alleviates Pulmonary Fibrosis by Regulating Abnormal Fibroblasts Through the STAT3/p-STAT3/GLUT1 Signaling Pathway".FRONTIERS in PHARMACOLOGY 13.(2022)
医学